ES2191942T3 - Nueva utilizacion de un antagonista especifico de los receptores 5ht2a. - Google Patents

Nueva utilizacion de un antagonista especifico de los receptores 5ht2a.

Info

Publication number
ES2191942T3
ES2191942T3 ES98928407T ES98928407T ES2191942T3 ES 2191942 T3 ES2191942 T3 ES 2191942T3 ES 98928407 T ES98928407 T ES 98928407T ES 98928407 T ES98928407 T ES 98928407T ES 2191942 T3 ES2191942 T3 ES 2191942T3
Authority
ES
Spain
Prior art keywords
new use
specific antagonist
5ht2a receptors
5ht2a
receptors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98928407T
Other languages
English (en)
Inventor
Francoise Cattelin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Synthelabo SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo SA filed Critical Sanofi Synthelabo SA
Application granted granted Critical
Publication of ES2191942T3 publication Critical patent/ES2191942T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Utilización del 1-(2-fluorofenil)-3-(4-hidroxifenil)-prop-2-en-1-ona-O-2-(demietilaminoetil)-oximo o de una de sus sales farmacéuticamente aceptables para la preparación de medicamentos útiles para el tratamiento del síndrome de la apnea del sueño.
ES98928407T 1997-06-26 1998-06-02 Nueva utilizacion de un antagonista especifico de los receptores 5ht2a. Expired - Lifetime ES2191942T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9707998A FR2765107B1 (fr) 1997-06-26 1997-06-26 Utilisation d'un antagoniste specifique des recepteurs 5ht2 pour la preparation de medicaments utiles dans le traitement du syndrome d'apnee du sommeil

Publications (1)

Publication Number Publication Date
ES2191942T3 true ES2191942T3 (es) 2003-09-16

Family

ID=9508467

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98928407T Expired - Lifetime ES2191942T3 (es) 1997-06-26 1998-06-02 Nueva utilizacion de un antagonista especifico de los receptores 5ht2a.

Country Status (28)

Country Link
US (1) US6143792A (es)
EP (1) EP1014960B1 (es)
JP (1) JP3503953B2 (es)
KR (1) KR20010014186A (es)
CN (1) CN1154485C (es)
AT (1) ATE232094T1 (es)
AU (1) AU728227B2 (es)
BG (1) BG104038A (es)
BR (1) BR9810337A (es)
CA (1) CA2295119C (es)
CZ (1) CZ291935B6 (es)
DE (1) DE69811248T2 (es)
EE (1) EE9900595A (es)
ES (1) ES2191942T3 (es)
FR (1) FR2765107B1 (es)
HU (1) HU229058B1 (es)
ID (1) ID23799A (es)
IL (1) IL133632A (es)
IS (1) IS2356B (es)
NO (1) NO325520B1 (es)
NZ (1) NZ502495A (es)
PL (1) PL190723B1 (es)
RU (1) RU2218917C2 (es)
SK (1) SK283845B6 (es)
TR (1) TR199903197T2 (es)
TW (1) TW580386B (es)
UA (1) UA59397C2 (es)
WO (1) WO1999000119A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7160898B2 (en) * 2001-12-14 2007-01-09 Board Of Trustees Of The University Of Illinois Pharmacological treatment for sleep apnea
US20060241164A1 (en) * 1998-02-27 2006-10-26 The Board Of Trustees Of The University Of Illinoi Pharmacological treatment for sleep apnea
DE69931042T2 (de) * 1998-02-27 2006-11-23 The Board Of Trustees Of The University Of Illinois, Urbana Stoffe mit serotoninartiger wirkung zur behandlung der schlafapnoe
FR2787328A1 (fr) 1998-12-22 2000-06-23 Sanofi Sa Utilisation d'un antagoniste des recepteurs 5ht2a pour la preparation de medicaments utiles dans le traitement des ronflements et du syndrome de haute resistance ou de resistance des voies aeriennes superieures
WO2000051582A2 (en) * 1999-03-01 2000-09-08 Sepracor Inc. Methods for treating apnea and apnea disorders using optically pure r(+)ondansetron
FR2804604B1 (fr) * 2000-02-09 2005-05-27 Sanofi Synthelabo Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac
DK1534391T3 (da) * 2002-07-19 2007-06-11 Biovitrum Ab Nye piperazinyl-pyrazinonderivater til behandling af 5-HT2A-recptor-relaterede forstyrrelser
JP2008524332A (ja) 2004-12-20 2008-07-10 コレジウム ファーマシューティカル， インク． 睡眠傷害のための医薬組成物
EP2365805A1 (en) * 2008-11-13 2011-09-21 Sanofi Method of treating sleep disorders using eplivanserin
EP2186511A1 (en) * 2008-11-13 2010-05-19 Sanofi-Aventis Method of treating sleep disorders using eplivanserin
EP2266554A1 (en) * 2009-05-26 2010-12-29 Sanofi-Aventis Method of treating sleep disorders using eplivanserin
WO2010079241A1 (es) 2009-01-12 2010-07-15 Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion Uso de antagonistas y/o agonistas inversos de los receptores cb1 para la preparación de medicamentos que incrementen la excitabilidad de las motoneuronas
EP2255726A1 (en) 2009-05-26 2010-12-01 Sanofi-Aventis Spectral profile of SWS enhancing drugs
EP2255807A1 (en) 2009-05-26 2010-12-01 Sanofi-Aventis Method of treating sleep disorders using the combination of eplivanserin and zolpidem
EP2269600A1 (en) * 2009-07-02 2011-01-05 Sanofi-Aventis Treatment of sleep disorders using eplivanserin in COPD patients

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2639942B1 (fr) * 1988-12-02 1991-03-29 Sanofi Sa Ethers oximes de propenone, procede pour leur preparation et compositions pharmaceutiques les contenant
CA2039102A1 (en) * 1990-03-29 1991-09-30 David W. Robertson Compounds affecting serotonin receptors
EP0517984A1 (en) * 1991-06-11 1992-12-16 Merrell Dow Pharmaceuticals Inc. Derivatives of amide analogs of certain methano bridged quinolizines
IL103106A (en) * 1991-09-25 1998-06-15 Sanofi Elf Ethers of thienocyclopentanone oximes, their preparation and pharmaceutical compositions containing them
RU2043125C1 (ru) * 1992-05-15 1995-09-10 Эдуард Арутюнович Петросян Способ профилактики осложнений неингаляционного наркоза

Also Published As

Publication number Publication date
EE9900595A (et) 2000-08-15
NO996442L (no) 2000-02-28
CN1265586A (zh) 2000-09-06
WO1999000119A1 (fr) 1999-01-07
ID23799A (id) 2000-05-11
SK283845B6 (sk) 2004-03-02
IL133632A0 (en) 2001-04-30
HU229058B1 (en) 2013-07-29
EP1014960A1 (fr) 2000-07-05
JP3503953B2 (ja) 2004-03-08
HK1028351A1 (en) 2001-02-16
IL133632A (en) 2003-10-31
TR199903197T2 (xx) 2000-05-22
FR2765107B1 (fr) 2000-03-24
NO996442D0 (no) 1999-12-23
ATE232094T1 (de) 2003-02-15
PL190723B1 (pl) 2005-12-30
CN1154485C (zh) 2004-06-23
CZ291935B6 (cs) 2003-06-18
KR20010014186A (ko) 2001-02-26
FR2765107A1 (fr) 1998-12-31
AU8024398A (en) 1999-01-19
RU2218917C2 (ru) 2003-12-20
DE69811248D1 (de) 2003-03-13
IS5316A (is) 1999-12-21
JP2001520678A (ja) 2001-10-30
BG104038A (en) 2001-04-30
DE69811248T2 (de) 2003-12-04
NZ502495A (en) 2000-10-27
PL337871A1 (en) 2000-09-11
IS2356B (is) 2008-04-15
US6143792A (en) 2000-11-07
HUP0002170A3 (en) 2001-12-28
SK184599A3 (en) 2000-06-12
BR9810337A (pt) 2000-09-05
UA59397C2 (uk) 2003-09-15
CA2295119A1 (en) 1999-01-07
EP1014960B1 (fr) 2003-02-05
CZ469599A3 (cs) 2000-04-12
AU728227B2 (en) 2001-01-04
HUP0002170A2 (hu) 2001-11-28
NO325520B1 (no) 2008-06-02
CA2295119C (en) 2007-02-13
TW580386B (en) 2004-03-21

Similar Documents

Publication Publication Date Title
CO5011096A1 (es) Medicamentos que contienen antagonistas del receptor 5-ht3 para el tratamiento de la ibs
UY25242A1 (es) Inhibidores de benzotiazol de la proteína tirosina cinasa
CO4340681A1 (es) Procedimientos de uso para la inhibicion de la perdida osea y la disminucion del colesterol en suero
NO20053106D0 (no) Oral, analgesisk doseringsform med forlenget frigivelse.
ES2196625T3 (es) Polidialilamina no sustituida para tratar la hipercolesterolemia.
MX9203444A (es) Medicamentos.
DE50008336D1 (de) Mehrschichttablette zur verabreichung einer fixen kombination von tramadol und diclofenac
ES2128761T3 (es) Formulacion de tirilazad con cosolvente para administracion parenteral.
EE9600118A (et) Uus peroraalne farmatseutiline annusvorm
AR025883A1 (es) Utilizacion de antagonistas de los receptores de los cannabinoides centrales para la preparacion de medicamentos
SV2003000633A (es) Nuevos tiadiazoles y oxadiazoles y su uso como inhibidores de fosfodiesterasa-7
ES2176106A1 (es) Comprimido matricial de liberacion prolongada de trimetazidina tras su administracion por via oral.
EE9700014A (et) Uus peroraalne ravimvorm, mis sisaldab omeprasooli magneesiumsoola
ES2159362T3 (es) Utilizacion de la 1-(2-naft-2-iletil)-4-(3-trifluorometilfenil)-1,2,3,6-tetrahidropiridina para la preparacion de medicamentos destinados para el tratamiento de la esclerosis lateral amiotrofica.
NO996442L (no) Anvendelse av en spesifikk antagonist for 5HT2 reseptorer for fremstilling av medisiner som er anvendbare for behandling av søvnapnésyndromet
AR023687A1 (es) Una composicion para el tratamiento de desordenes de la retina externa y el uso de un antagonista de glutamato para la manufactura de un medicamento parael tratamiento de desordenes de la retina externa
CO4230161A1 (es) Compuestos neuroprotectores que bloquean los receptores de aminoacidos excitativos y antiisquemicos
NO20014855D0 (no) N-(2-fenyl-4-aminobutyl)-1-naftamider som neurokinin-1- reseptorantagonister
ES2135412T3 (es) Uso de antagonistas o agonistas parciales del receptor 5-ht 1a para el tratamiento y la prevencion de trastornos cognitivos.
AR029588A1 (es) Nueva forma (r)-n-[5-metil-8-(4-metilpiperazina-1-il)-1,2,3,4-tetrahidro-2-naftil]-4-morfolinobenzamida
UY27910A1 (es) Uso de un derivado de amina cíclica específico o de sus sales farmacéuticamente aceptables para tratar o prevenir la insuficiencia cardiaca
ES2191908T3 (es) 4-aminopirrol(3,2-d)pirimidinas como antagonistas del receptor del neuropeptido.
UY26329A1 (es) Antagonistas de los receptores de vitronectina
AR038316A1 (es) Ambroxol para el tratamiento de dolores cronicos
MX9204212A (es) Preparado de combinacion farmaceutico.